Table 1 Data and immunophenotype of AML FAB-M1 patient BMMCs
Gender | Female | ||
|---|---|---|---|
Age: | 21Â years old | ||
Diagnosed with: | AML FAB-M1; AML without maturation according to WHO classification [42] | ||
Blast titer: | 89.7% blast in the marrow at diagnosis | ||
Case history | Â | One course of induction chemotherapy following HAM protocol high dose cytarabine with mitoxantrone [49] | |
Current status: | Complete remission acheived by induction chemotherapy (HAM) | ||
Myeloid cells % (in blast gate) | Co-expression (cross-lineage) % (in blast gate) | ||
CD 34 | 89.6% | CD34/CD56 | 47.9% |
CD 33 | <19% | CD34/CD7 | 12.3% |
CD 123 | n.d. at diagnosis | CD34/HLA-DR | 90.5% |
CD 117 | < 1% | CD34/CD7 | 12.3% |
CD 38 | 89.9% | Â | Â |
cy MPO | 41.7 | Â | Â |